DK3672976T3 - Bcl-2-hæmmere - Google Patents
Bcl-2-hæmmere Download PDFInfo
- Publication number
- DK3672976T3 DK3672976T3 DK18765259.9T DK18765259T DK3672976T3 DK 3672976 T3 DK3672976 T3 DK 3672976T3 DK 18765259 T DK18765259 T DK 18765259T DK 3672976 T3 DK3672976 T3 DK 3672976T3
- Authority
- DK
- Denmark
- Prior art keywords
- bcl
- inhibitors
- Prior art date
Links
- 239000012664 BCL-2-inhibitor Substances 0.000 title 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/76—Chemiluminescence; Bioluminescence
- G01N21/763—Bioluminescence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Plasma & Fusion (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762549081P | 2017-08-23 | 2017-08-23 | |
| US201862615007P | 2018-01-09 | 2018-01-09 | |
| PCT/US2018/047444 WO2019040573A1 (en) | 2017-08-23 | 2018-08-22 | Bcl-2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3672976T3 true DK3672976T3 (da) | 2024-03-04 |
Family
ID=63490700
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18765259.9T DK3672976T3 (da) | 2017-08-23 | 2018-08-22 | Bcl-2-hæmmere |
| DK18765254.0T DK3672975T3 (da) | 2017-08-23 | 2018-08-22 | Kondenserede, heterocykliske derivater som bcl-2-hæmmere til behandling af neoplastiske sygdomme |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18765254.0T DK3672975T3 (da) | 2017-08-23 | 2018-08-22 | Kondenserede, heterocykliske derivater som bcl-2-hæmmere til behandling af neoplastiske sygdomme |
Country Status (15)
| Country | Link |
|---|---|
| US (7) | US11365206B2 (da) |
| EP (3) | EP3672975B1 (da) |
| JP (2) | JP7467332B2 (da) |
| KR (2) | KR102705861B1 (da) |
| CN (4) | CN111448198B (da) |
| AU (2) | AU2018322059C1 (da) |
| CA (2) | CA3073446A1 (da) |
| DK (2) | DK3672976T3 (da) |
| ES (2) | ES2971457T3 (da) |
| FI (2) | FI3672976T3 (da) |
| IL (1) | IL272762B2 (da) |
| MX (2) | MX2020002032A (da) |
| SG (1) | SG11202001553UA (da) |
| WO (2) | WO2019040573A1 (da) |
| ZA (1) | ZA202001301B (da) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3073446A1 (en) | 2017-08-23 | 2019-02-28 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| SI3788042T1 (sl) | 2018-04-29 | 2025-06-30 | Beigene Switzerland Gmbh | Zaviralci BCL-2 |
| WO2020041405A1 (en) | 2018-08-22 | 2020-02-27 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| WO2020140005A2 (en) | 2018-12-29 | 2020-07-02 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| WO2021066873A1 (en) | 2019-10-03 | 2021-04-08 | Newave Pharmaceutical Inc. | Condensed heterocycles as bcl-2 inhibitors |
| CN114929689B (zh) * | 2019-10-28 | 2024-08-27 | 百济神州有限公司 | Bcl-2抑制剂 |
| WO2021133817A1 (en) | 2019-12-27 | 2021-07-01 | Guangzhou Lupeng Pharmaceutical Company Ltd. | 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
| WO2021173523A1 (en) | 2020-02-24 | 2021-09-02 | Newave Pharmaceutical Inc. | Hot melt extruded solid dispersions containing a bcl2 inhibitor |
| WO2021208963A1 (en) | 2020-04-15 | 2021-10-21 | Beigene, Ltd. | Bcl-2 inhibitor |
| WO2022140224A1 (en) | 2020-12-22 | 2022-06-30 | Newave Pharmaceutical Inc. | 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
| CN113694059B (zh) * | 2021-03-24 | 2023-09-26 | 浙江大学 | Nl101在制备治疗急性、慢性排斥反应药物中的应用 |
| WO2023122000A1 (en) * | 2021-12-20 | 2023-06-29 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| US20250099481A1 (en) * | 2022-01-12 | 2025-03-27 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| TW202340210A (zh) | 2022-01-21 | 2023-10-16 | 美商艾伯維有限公司 | 1,3,4,7-四氫-2H-吡咯并[3',2':5,6]吡啶并[2,3-b][1,4]氮呯Bcl-2抑制劑 |
| CN116270660A (zh) * | 2023-03-30 | 2023-06-23 | 广州麓鹏制药有限公司 | 一种含Bcl-2/Bcl-xl抑制剂的组合物及其制备方法与应用 |
| CN116236583A (zh) * | 2023-03-30 | 2023-06-09 | 广州麓鹏制药有限公司 | 一种含Bcl-2/Bcl-xl抑制剂的组合物及其制备方法与应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| JP4336678B2 (ja) | 2003-09-04 | 2009-09-30 | 株式会社日立超エル・エス・アイ・システムズ | 半導体装置 |
| US7767684B2 (en) | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
| WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| US8614318B2 (en) | 2003-11-13 | 2013-12-24 | Abbvie Inc. | Apoptosis promoters |
| US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| US7642260B2 (en) | 2003-11-13 | 2010-01-05 | Abbott Laboratories, Inc. | Apoptosis promoters |
| WO2008064116A2 (en) | 2006-11-16 | 2008-05-29 | Abbott Laboratories | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection |
| GB0623209D0 (en) * | 2006-11-21 | 2007-01-03 | F2G Ltd | Antifungal agents |
| WO2009036035A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Bcl-2 inhibitors |
| KR101585848B1 (ko) | 2007-11-16 | 2016-01-15 | 애브비 인코포레이티드 | 관절염의 치료 방법 |
| UA108193C2 (uk) * | 2008-12-04 | 2015-04-10 | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
| US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| RU2497822C2 (ru) | 2008-12-05 | 2013-11-10 | Эббви Инк. | Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US9034875B2 (en) | 2009-05-26 | 2015-05-19 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| UY32668A (es) | 2009-05-26 | 2010-12-31 | Abbott Lab | Agentes inductores de la apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes |
| TWI520960B (zh) | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
| JP5743482B2 (ja) | 2010-10-15 | 2015-07-01 | 株式会社アルファ | エスカッション部材のハンドルベースへの連結方法 |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| EP2632436B1 (en) | 2010-10-29 | 2018-08-29 | Abbvie Inc. | Solid dispersions containing an apoptosis-inducing agent |
| JP6141188B2 (ja) | 2010-11-23 | 2017-06-07 | アッヴィ・インコーポレイテッド | アポトーシス誘導剤の塩および結晶の形態 |
| EP2935284A4 (en) * | 2012-12-21 | 2016-04-27 | Abbvie Inc | HETEROCYCLIC MODULATORS OF HORMONE NUCLEAR RECEPTORS |
| BR122021025053B1 (pt) | 2013-03-13 | 2022-09-06 | Abbvie Inc | Processo para a preparação de um agente indutor de apoptose |
| CN104513252B (zh) * | 2013-09-26 | 2017-11-10 | 广东东阳光药业有限公司 | 取代脲衍生物及其在药物中的应用 |
| WO2017132474A1 (en) * | 2016-01-30 | 2017-08-03 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| US11053239B2 (en) | 2017-01-07 | 2021-07-06 | Fochon Pharmaceuticals, Ltd. | Compounds as BLC-2-selective apoptosis-inducing agents |
| SI3612531T1 (sl) | 2017-04-18 | 2022-11-30 | Shanghai Fochon Pharmaceutical Co., Ltd. | Sredstva, ki sprožajo apoptozo |
| CA3073446A1 (en) | 2017-08-23 | 2019-02-28 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| WO2020041405A1 (en) | 2018-08-22 | 2020-02-27 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| WO2020140005A2 (en) | 2018-12-29 | 2020-07-02 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| WO2021066873A1 (en) | 2019-10-03 | 2021-04-08 | Newave Pharmaceutical Inc. | Condensed heterocycles as bcl-2 inhibitors |
| US20230119463A1 (en) | 2019-12-27 | 2023-04-20 | Newave Pharmaceutical Inc. | 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
-
2018
- 2018-08-22 CA CA3073446A patent/CA3073446A1/en active Pending
- 2018-08-22 ES ES18765259T patent/ES2971457T3/es active Active
- 2018-08-22 CN CN201880067185.4A patent/CN111448198B/zh active Active
- 2018-08-22 CA CA3073445A patent/CA3073445A1/en active Pending
- 2018-08-22 CN CN201880067225.5A patent/CN111511748B/zh active Active
- 2018-08-22 DK DK18765259.9T patent/DK3672976T3/da active
- 2018-08-22 CN CN202310267471.8A patent/CN116425771A/zh active Pending
- 2018-08-22 AU AU2018322059A patent/AU2018322059C1/en active Active
- 2018-08-22 WO PCT/US2018/047444 patent/WO2019040573A1/en not_active Ceased
- 2018-08-22 ES ES18765254T patent/ES2948287T3/es active Active
- 2018-08-22 FI FIEP18765259.9T patent/FI3672976T3/fi active
- 2018-08-22 MX MX2020002032A patent/MX2020002032A/es unknown
- 2018-08-22 IL IL272762A patent/IL272762B2/en unknown
- 2018-08-22 CN CN202310439771.XA patent/CN116621860A/zh active Pending
- 2018-08-22 FI FIEP18765254.0T patent/FI3672975T3/fi active
- 2018-08-22 EP EP18765254.0A patent/EP3672975B1/en active Active
- 2018-08-22 AU AU2018321496A patent/AU2018321496B2/en active Active
- 2018-08-22 KR KR1020207008178A patent/KR102705861B1/ko active Active
- 2018-08-22 JP JP2020510610A patent/JP7467332B2/ja active Active
- 2018-08-22 DK DK18765254.0T patent/DK3672975T3/da active
- 2018-08-22 EP EP23167453.2A patent/EP4227311A1/en active Pending
- 2018-08-22 WO PCT/US2018/047411 patent/WO2019040550A1/en not_active Ceased
- 2018-08-22 JP JP2020510576A patent/JP7467331B2/ja active Active
- 2018-08-22 MX MX2020002033A patent/MX2020002033A/es unknown
- 2018-08-22 SG SG11202001553UA patent/SG11202001553UA/en unknown
- 2018-08-22 EP EP18765259.9A patent/EP3672976B1/en active Active
- 2018-08-22 KR KR1020207008179A patent/KR102680163B1/ko active Active
-
2020
- 2020-02-20 US US16/795,720 patent/US11365206B2/en active Active
- 2020-02-20 US US16/795,884 patent/US11279711B2/en active Active
- 2020-02-28 ZA ZA2020/01301A patent/ZA202001301B/en unknown
-
2022
- 2022-03-18 US US17/698,289 patent/US11680072B2/en active Active
- 2022-06-15 US US17/840,957 patent/US11993610B2/en active Active
-
2023
- 2023-05-03 US US18/142,842 patent/US12410190B2/en active Active
-
2024
- 2024-04-22 US US18/641,869 patent/US20240425520A1/en not_active Abandoned
- 2024-12-06 US US18/971,214 patent/US20250179090A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3788042T (lt) | Bcl-2 inhibitoriai | |
| IL283639A (en) | Kif18a inhibitors | |
| IL269196A (en) | Novel inhibitors | |
| DK3672976T3 (da) | Bcl-2-hæmmere | |
| IL263586A (en) | Inhibitors of the menin-mll interaction | |
| EP4051676A4 (en) | BCL-2 INHIBITORS | |
| EP3541932A4 (en) | INHIBITORS OF CRISPR-CAS9 | |
| DK3612525T3 (da) | Pd-1-/pd-l1-inhibitorer | |
| DK3571192T3 (da) | Jak1-selektive inhibitorer | |
| DK3497103T3 (da) | Pyridopyrimdinon-cdk2/4/6-inhibitorer | |
| IL280863A (en) | Autotaxin inhibitors and uses thereof | |
| LT3303334T (lt) | Tirozinkinazės inhibitoriai | |
| DK3442972T3 (da) | Bromdomænehæmmere | |
| IL294381A (en) | Pcna inhibitors | |
| HUE042335T2 (hu) | ROR-gamma dihidropirrolopiridin inhibitorai | |
| DK3681884T3 (da) | Rad51-inhibitorer | |
| EP3313828A4 (en) | METALLO-BETA-Lactamase INHIBITORS | |
| DK3630744T3 (da) | Pyrazol-magl-inhibitorer | |
| DK3186242T3 (da) | Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere | |
| MA43367A (fr) | Inhibiteurs de métallo-bêta-lactamases | |
| EP3600301A4 (en) | KDM4 INHIBITORS | |
| MA46280A (fr) | Inhibiteurs de la dopamine-b-hydroxylase | |
| IL281514A (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
| DK3280405T3 (da) | Inhibitorer og anvendelser deraf | |
| HUE054460T2 (hu) | Immunproteaszóma-gátlók |